Belgian biopharmaceutical company Oxurion NV (Euronext Brussels:OXUR) revealed on Thursday that it has secured financing from Atlas Special Opportunities to acquire 72% of the share capital of French biometrics specialist Axiodis CRO
The transaction is expected to close on 1 August 2025, following successful due diligence and the satisfaction of all conditions precedent.
This acquisition aligns with Oxurion's strategy to build an integrated clinical data platform supporting key stages of therapeutic development.
Oxurion aims to leverage Axiodis' human and technical expertise to strengthen its position as a strategic partner in clinical research.
The company has also identified additional acquisition targets in France and across Europe to support its ambition of creating a leading European clinical data hub.
Imaging Biometrics soft closes Phase 1 Ttrial for oral GaM in glioblastoma
Viatris reports MR-139 Phase 3 study in blepharitis did not meet primary endpoint
CorestemChemon partners with ATG Lifetech to provide next-gen preclinical services
EQT agrees to acquire majority stake in Adalvo
Sanofi finalizes acquisition of Blueprint Medicines to expand rare disease and immunology portfolio
Clarity Pharmaceuticals' Co-PSMA trial completes recruitment
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
Actuate Therapeutics advances Ewing Sarcoma trial following positive Phase 1 results
Oxurion secures funding to acquire majority stake in Axiodis CRO
Genetic Leap's GL-IL2-138 receives FDA IND clearance
Amphix Bio's AMFX-200 receives US FDA Orphan Drug Designation to treat acute spinal cord injury
Innovent Biologics' Phase 1 anti-CLDN18.2 ADC (IBI343) results published in Nature Medicine
Hemogenyx wins USD120,000 grant to advance scalable CAR-T manufacturing